Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001237717 | SCV001410490 | pathogenic | Bethlem myopathy 1 | 2021-08-18 | criteria provided, single submitter | clinical testing | This sequence change falls in intron 9 of the COL6A2 gene. It does not directly change the encoded amino acid sequence of the COL6A2 protein, but it affects a nucleotide within the consensus splice site of the intron. This variant is present in population databases (rs750755566, ExAC 0.006%). This variant has been observed in individual(s) with clinical features of type VI collagenopathy (Invitae). In at least one individual the variant was observed to be de novo. Nucleotide substitutions within the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. For these reasons, this variant has been classified as Pathogenic. |
Revvity Omics, |
RCV003490147 | SCV004235447 | uncertain significance | not provided | 2023-06-02 | criteria provided, single submitter | clinical testing |